RegeneRx
Contact Us


Overview

Our Mission

To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. More>>

Stock Quote
RGN (Common Stock)
ExchangeNYSE AMEX (US Dollar)
Price$0.59
Change (%) Stock is Down 0.02 (1.67%)
Volume97,718
Data as of 03/09/10 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
Download Documentation Fact Sheet July 2009
Recent NewsMore >>
DateTitle 
03/05/10Researchers Report that Thymosin beta 4 Improves Neurological Function after StrokePrinter Friendly Version
03/02/10RegeneRx Biopharmaceuticals' President and CEO to Present at 22nd Annual Roth Capital Growth Stock ConferencePrinter Friendly Version
02/26/10Researchers Report Novel Biological Properties of Fragments of Thymosin Beta 4Printer Friendly Version
02/08/10Researchers Report Elevated Levels of TB4 Levels Predict Patient Survival in Hepatitis B Virus-related Liver FailurePrinter Friendly Version
Contact Information
Primary IR Contact
C. Neil Lyons
Chief Financial Officer
RegeneRx Biopharmaceuticals, Inc.
15245 Shady Grove Road
Suite 470
Rockville, MD 20850
Phone: 301-208-9191
Fax: 301-208-9194
E-mail: info@regenerx.com

Transfer Agent
American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
Phone: 800-937-5449


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

     
home|Contact Us|Resources|Site Map|
Search